Urate and the risk of Parkinson's disease in men and women

被引:40
作者
Cortese, Marianna [1 ,2 ,3 ,4 ]
Riise, Trond [2 ,4 ]
Engeland, Anders [4 ,5 ]
Ascherio, Alberto [3 ,6 ,7 ,8 ]
Bjornevik, Kjetil [2 ,3 ,4 ]
机构
[1] Univ Bergen, Dept Clin Med, Bergen, Norway
[2] Haukeland Hosp, Dept Neurol, Bergen, Norway
[3] Harvard TH Chan Sch Publ Hlth, Dept Nutr, 677 Huntington Ave, Boston, MA 02115 USA
[4] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway
[5] Norwegian Inst Publ Hlth, Dept Pharmacoepidemiol, Bergen, Norway
[6] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[7] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA
[8] Harvard Med Sch, Boston, MA USA
关键词
Parkinson's disease; Cohort studies; Risk factors in epidemiology; Differences by sex; URIC-ACID LEVELS; PLASMA URATE; GOUT; NEUROPROTECTION;
D O I
10.1016/j.parkreldis.2018.03.026
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: High urate levels have consistently been associated with lower Parkinson's disease (PD) risk among men, but the association is less clear among women. In this study we prospectively investigated the association between high uric acid levels and PD, evaluating potential differences by sex and age. Methods: This historical cohort study included the entire Norwegian population alive and at least 18 years old on 01/01/2004. We retrieved use of urate-lowering drugs, a marker of high urate levels/gout, from the Norwegian Prescription Database, and followed individuals from 01/01/2005 to PD onset, emigration, death, or end of follow-up on 31/12/2013. We identified 4523 incident PD cases during follow-up, and used Cox regression to estimate hazard ratios (HRadj) and 95% confidence intervals (CI), adjusting for sex, age, and level of education. We also tested for effect modification by sex and age. Results: Exposure to urate-lowering drugs was associated with a significantly lower PD risk (HRadj = 0.80, 95% CI: 0.68-0.95). The association was more marked in men (HRadj = 0.77, 95% CI: 0.63-0.94), compared to women (HRadj = 0.89, 95% CI: 0.65-1.22), but the difference was not significant (p for effect modification = 0.61). The association varied significantly by age among women (p = 0.01) with a protective effect suggested only at higher age (above 70 years) when urate levels are higher than pre-menopausally (HR = 0.65, 95% CI: 0.41-1.03), but not in men (p = 0.61). Conclusion: These findings suggest that urate may be protective against PD in both men and women. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 29 条
  • [1] Gout and risk of Parkinson disease -: A prospective study
    Alonso, Alvaro
    Garcia Rodriguez, Luis A.
    Logroscino, Giancarlo
    Hernan, Miguel A.
    [J]. NEUROLOGY, 2007, 69 (17) : 1696 - 1700
  • [2] Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study
    Alves, G.
    Mueller, B.
    Herlofson, K.
    HogenEsch, I.
    Telstad, W.
    Aarsland, D.
    Tysnes, O-B
    Larsen, J. P.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (08) : 851 - 857
  • [3] [Anonymous], 2018, DEF GEN CONS DAIL DE
  • [4] The epidemiology of Parkinson's disease: risk factors and prevention
    Ascherio, Alberto
    Schwarzschild, Michael A.
    [J]. LANCET NEUROLOGY, 2016, 15 (12) : 1255 - 1270
  • [5] Becker M.A., 2016, PREVENTION RECURRENT
  • [6] Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4
  • [7] Plasma Urate and Parkinson's Disease in the Atherosclerosis Risk in Communities (ARIC) Study
    Chen, Honglei
    Mosley, Thomas H.
    Alonso, Alvaro
    Huang, Xuemei
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 169 (09) : 1064 - 1069
  • [8] Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration
    Chen, Xiqun
    Burdett, Thomas C.
    Desjardins, Cody A.
    Logan, Robert
    Cipriani, Sara
    Xu, Yuehang
    Schwarzschild, Michael A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (01) : 300 - 305
  • [9] Cipriani S., 2012, PLOS ONE, V7
  • [10] Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease
    Clarke, CE
    [J]. LANCET NEUROLOGY, 2004, 3 (08) : 466 - 474